<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">ACM</journal-id><journal-title-group><journal-title>Advances in Clinical Medicine</journal-title></journal-title-group><issn pub-type="epub">2161-8712</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.12677/ACM.2021.113194</article-id><article-id pub-id-type="publisher-id">ACM-41330</article-id><article-categories><subj-group subj-group-type="heading"><subject>ACM20210300000_15065790.pdf</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>医药卫生</subject></subj-group></article-categories><title-group><article-title>
 
 
  FBXW7与原发性肝癌发生的关系
  Relationship between FBXW7 and the Occurrence of Primary Liver Cancer
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>谭</surname><given-names>智勇</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>李</surname><given-names>春明</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>龚</surname><given-names>建平</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib></contrib-group><aff id="aff2"><addr-line>重庆市云阳县人民医院，重庆 云阳县</addr-line></aff><aff id="aff3"><addr-line>重庆医科大学附属第二医院肝胆外科，重庆</addr-line></aff><aff id="aff1"><addr-line>null</addr-line></aff><pub-date pub-type="epub"><day>04</day><month>03</month><year>2021</year></pub-date><volume>11</volume><issue>03</issue><fpage>1362</fpage><lpage>1366</lpage><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
  
    SCF (SKP1-Cullin 1-F-box protein) E3泛素连接酶作为E3泛素连接酶中最重要的家族，负责人类机体内多种蛋白的降解。其中，F-box蛋白作为SCF E3泛素连接酶的底物受体，其功能失调在包括原发性肝癌在内的多种人类癌症中发挥着重要的作用。本文将根据国内外文献报道FBXW7在原发性肝癌发生发展中发挥的重要角色，为未来针对FBXW7及其信号通路的分子靶向药物的开发在原发性肝癌中的运用提供方向。
    As the most important family of E3 ubiquitin ligases, SCF (SKP1-Cullin1-F-box protein) E3 ubiquitin ligases are responsible for the degradation of a variety of proteins in the human body. Among all the components of SCF E3 ubiquitin ligases, aberrant regulation of the F-box protein plays an important role in a variety of human cancers, including primary liver cancer. In this paper, we will report the important role of FBXW7 in the occurrence and development of primary liver cancer according to domestic and foreign literatures. It also provides a direction for the exploitation of molecular targeting drugs of FBXW7 and its signaling pathway in the application of primary liver cancer in the future. 
  
 
</p></abstract><kwd-group><kwd>FBXW7，原发性肝癌，F-Box蛋白，E3泛素连接酶，分子靶向药物, FBXW7</kwd><kwd> Primary Liver Cancer</kwd><kwd> F-Box Proteins</kwd><kwd> E3 Ubiquitin Ligases</kwd><kwd> 
Molecular Targeting Drugs</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>摘要</title><p>SCF (SKP1-Cullin 1-F-box protein) E3泛素连接酶作为E3泛素连接酶中最重要的家族，负责人类机体内多种蛋白的降解。其中，F-box蛋白作为SCF E3泛素连接酶的底物受体，其功能失调在包括原发性肝癌在内的多种人类癌症中发挥着重要的作用。本文将根据国内外文献报道FBXW7在原发性肝癌发生发展中发挥的重要角色，为未来针对FBXW7及其信号通路的分子靶向药物的开发在原发性肝癌中的运用提供方向。</p></sec><sec id="s2"><title>关键词</title><p>FBXW7，原发性肝癌，F-Box蛋白，E3泛素连接酶，分子靶向药物</p></sec><sec id="s3"><title>Relationship between FBXW7 and the Occurrence of Primary Liver Cancer</title><p>Zhiyong Tan<sup>1</sup>, Chunming Li<sup>2</sup>, Jianping Gong<sup>2</sup></p><p><sup>1</sup>Yunyang Hospital, People’s Hospital of Chongqing, Yunyang County Chongqing</p><p><sup>2</sup>Department of Hepatobiliary Surgery, The Second Affiliated Hospital of Chongqing Medical University, Chongqing</p><p><img src="//html.hanspub.org/file/77-1572072x4_hanspub.png" /></p><p>Received: Feb. 23<sup>rd</sup>, 2021; accepted: Mar. 11<sup>th</sup>, 2021; published: Mar. 30<sup>th</sup>, 2021</p><p><img src="//html.hanspub.org/file/77-1572072x5_hanspub.png" /></p></sec><sec id="s4"><title>ABSTRACT</title><p>As the most important family of E3 ubiquitin ligases, SCF (SKP1-Cullin1-F-box protein) E3 ubiquitin ligases are responsible for the degradation of a variety of proteins in the human body. Among all the components of SCF E3 ubiquitin ligases, aberrant regulation of the F-box protein plays an important role in a variety of human cancers, including primary liver cancer. In this paper, we will report the important role of FBXW7 in the occurrence and development of primary liver cancer according to domestic and foreign literatures. It also provides a direction for the exploitation of molecular targeting drugs of FBXW7 and its signaling pathway in the application of primary liver cancer in the future.</p><p>Keywords:FBXW7, Primary Liver Cancer, F-Box Proteins, E3 Ubiquitin Ligases, Molecular Targeting Drugs</p><disp-formula id="hanspub.41330-formula65"><graphic xlink:href="//html.hanspub.org/file/77-1572072x6_hanspub.png"  xlink:type="simple"/></disp-formula><p>Copyright &#169; 2021 by author(s) and Hans Publishers Inc.</p><p>This work is licensed under the Creative Commons Attribution International License (CC BY 4.0).</p><p>http://creativecommons.org/licenses/by/4.0/</p><p><img src="//html.hanspub.org/file/77-1572072x7_hanspub.png" /> <img src="//html.hanspub.org/file/77-1572072x8_hanspub.png" /></p></sec><sec id="s5"><title>1. 引言</title><p>泛素–蛋白酶体系统(UPS)通过靶向泛素化和蛋白酶体降解细胞内蛋白调节多种生理学进程包括细胞周期，细胞生长，转录和细胞凋亡 [<xref ref-type="bibr" rid="hanspub.41330-ref1">1</xref>]。泛素化的过程由三个连续的酶促反应构成。泛素(Ub)首先由泛素激活酶(E1)以ATP依赖的方式激活，激活的泛素随后转移到泛素结合酶(E2)上，然后通过泛素连接酶(E3)催化连接到目标蛋白上。截至目前，人类已经发现了超过700种E3泛素连接酶，主要分为两大类：RING (Really Interesting New Gene)和HECT (Homologous to the E6-AP Carboxyl Terminus) [<xref ref-type="bibr" rid="hanspub.41330-ref2">2</xref>]。其中，作为RING家族中最大的成员，SKP1-cullin 1-F-box protein (SCF)，在从酵母到人的真核细胞中高度保守。SCF由四个组分构成：Skp1，Cul1，ROC1/Rbx1 (RING蛋白)和F-box蛋白。F-box蛋白作为底物蛋白的受体，根据其与SKP1连接的结构域的特征分为三大亚类：FBXW，FBXL和FBXO。FBXW亚类包含WD40重复序列，该序列被认为具有调节蛋白与蛋白之间相互作用的功能。FBXL亚类富含亮氨酸重复序列。FBXO亚类既不含WD40重复序列也不含富亮氨酸重复序列 [<xref ref-type="bibr" rid="hanspub.41330-ref3">3</xref>]。其中FBXW7与原发性肝癌发生的关系最为密切。Fbxw7 (又名Fbx7和Cdc4)定位于人类4q32染色体，由三种亚型(FBXW7α, FBXW7β, FBXW7γ)组成 [<xref ref-type="bibr" rid="hanspub.41330-ref4">4</xref>]。三种亚型编码的不同蛋白由相同的C端保守相互作用结构域和不同的N端同种异型结构域构成，分别定位在核质，胞质和核仁，实现底物蛋白在细胞不同腔室内的降解。FBXW7α在组织样本和细胞系中广泛表达，通过对促癌蛋白c-JUN、cyclin E、c-MYC、NOTCH1、MCL1等的泛素化起到抑癌作用。FBXW7β在不同组织中表达有较大差异，且Fbxw7β的甲基化与乳腺癌患者的高总生存率相关。FBXW7γ的不稳定可引起c-MYC表达的增加 [<xref ref-type="bibr" rid="hanspub.41330-ref5">5</xref>]。</p><p>原发性肝癌是目前癌症相关死亡的第二大原因 [<xref ref-type="bibr" rid="hanspub.41330-ref6">6</xref>]。大约90%的原发性肝癌与已知的潜在病因有关，最常见的是慢性病毒性肝炎(B型和C型)、酒精摄入和黄曲霉素暴露。在世界范围内，大约54%的病例可归因于HBV感染，31%可归因于HCV感染，而在东亚，超过60%的病例与HBV感染相关 [<xref ref-type="bibr" rid="hanspub.41330-ref7">7</xref>]。慢性肝病患者体内存在着持续的肝脏炎症、纤维化和异常的肝细胞。这些异常可导致肝硬化，并有利于一系列的遗传突变和表观遗传事件的发生，最终形成异常增生结节，有关分子的进一步改变使增生异常的细胞具有增殖性、侵袭性，获得了生存优势，从而完成了向肝癌的转变。因此，越来越多的研究致力于原发性肝癌发生发展中的分子改变，并从中探索新的分子靶向药物，为肝癌的治疗开辟新的道路。本文将根据最新的国内外文献报道FBXW7在原发性肝癌发生发展中发挥的重要角色，为未来FBXW7及其信号通路作为原发性肝癌治疗靶点提供依据。</p></sec><sec id="s6"><title>2. FBXW7在恶性肿瘤中的研究进展</title><p>多种人类恶性肿瘤中存在FBXW7基因缺失和失活突变。FBXW7主要通过靶向泛素化和降解促癌蛋白c-JUN、cyclin E、c-MYC、NOTCH1、MCL1、TGIF1和KLF5等来抑制增殖 [<xref ref-type="bibr" rid="hanspub.41330-ref8">8</xref>]。这些促癌蛋白多为转录因子，通过调节一系列的转录过程，对癌症的发生发展起重要的作用，包括增殖、分化、转移和凋亡。</p><p>因此，FBXW7被认为是重要的肿瘤抑制蛋白。特别是在血液系统恶性肿瘤中，T细胞或造血干细胞中Fbxw7缺失可引起T细胞急性淋巴细胞白血病，并可通过致癌基因如Notch1的激活来加速T细胞急性淋巴细胞白血病。Fbxw7ARG/+小鼠没有发生T细胞急性淋巴细胞白血病，但Fbxw7与Notch1失调共同引发T细胞急性淋巴细胞白血病，这在很大程度上依赖于c-Myc稳定性的增加 [<xref ref-type="bibr" rid="hanspub.41330-ref9">9</xref>]。除了NOTCH1和c-MYC外，cyclin E的失调也是Fbxw7引起T细胞急性淋巴细胞白血病的关键因素 [<xref ref-type="bibr" rid="hanspub.41330-ref10">10</xref>]。此外，在人类早期结直肠癌中发现存在FBXW7的突变。小鼠肠道中Fbxw7的缺失虽未导致结直肠癌，但可与人类结直肠癌中常见的其他突变(如APC或p53失活)共同加速腺瘤的形成 [<xref ref-type="bibr" rid="hanspub.41330-ref11">11</xref>]。</p></sec><sec id="s7"><title>3. FBXW7在原发性肝癌中的研究进展</title><sec id="s7_1"><title>3.1. FBXW7与原发性肝癌的发生发展</title><p>近年来，越来越多的研究发现FBXW7失调在原发性肝癌发生发展中起到重要作用。多种蛋白的异常表达导致FBXW7在原发性肝癌患者中下调。MAP3K13磷酸化E3泛素连接酶TRIM25减少其多聚泛素化和蛋白酶体降解，稳定的TRIM25直接降解FBXW7α促进肿瘤的发生发展 [<xref ref-type="bibr" rid="hanspub.41330-ref12">12</xref>]。wnt3a处理或β-catenin转染的HepG2和Hep3B细胞FBXW7表达下调 [<xref ref-type="bibr" rid="hanspub.41330-ref13">13</xref>]。然而某些蛋白的过表达可引起FBXW7表达上调，从而起到抑癌作用。体内和体外实验表明CASC抑制肝癌的侵犯、转移和上皮间质转化 [<xref ref-type="bibr" rid="hanspub.41330-ref14">14</xref>]。</p><p>此外，多种促癌micro-RNAs在原发性肝癌组织中过表达。miR-155-3p在体外实验中促进肝癌细胞增殖，在体内实验中促进成瘤 [<xref ref-type="bibr" rid="hanspub.41330-ref15">15</xref>]。miR-223在肝癌细胞株中过表达并表现出对索拉菲尼的抵抗 [<xref ref-type="bibr" rid="hanspub.41330-ref16">16</xref>]。miR-367在体外实验中促进肝癌细胞的侵袭、转移。作为wnt/β-catenin信号通路重要的下游分子，miR-770在HepG2和Hep3B细胞中表达增加，从而抑制FBXW7的表达 [<xref ref-type="bibr" rid="hanspub.41330-ref13">13</xref>]。miR-106a在原发性肝癌患者组织和肝癌细胞系中表达增加，敲除miR-106a可抑制肝癌细胞的侵袭和转移能力，并增强放疗敏感性 [<xref ref-type="bibr" rid="hanspub.41330-ref17">17</xref>]。</p></sec><sec id="s7_2"><title>3.2. FBXW7与原发性肝癌的临床特征</title><p>ZHU ZZ等的研究利用aCGH和表达微阵列发现原发性肝癌患者组织中Fbxw7基因水平拷贝数改变及RNA表达下调 [<xref ref-type="bibr" rid="hanspub.41330-ref18">18</xref>]。FBXW7在原发性肝癌患者组织中显著下调且与较差的临床病理特点(肿瘤体积大，血管侵犯，高病理学分级，高TNM分期)相关。研究表明，FBXW7表达较高的原发性肝癌患者有较高的5年生存率 [<xref ref-type="bibr" rid="hanspub.41330-ref19">19</xref>] [<xref ref-type="bibr" rid="hanspub.41330-ref20">20</xref>] [<xref ref-type="bibr" rid="hanspub.41330-ref21">21</xref>]。</p></sec></sec><sec id="s8"><title>4. 研究展望</title><p>综上所述，基因突变或单倍体缺失导致FBXW7蛋白表达下调而失去抑癌作用是包括原发性肝癌在内的多种人类恶性肿瘤发生的重要原因。FBXW7通过对多种底物的降解发挥抑癌作用。FBXW7表达下调导致促癌蛋白YAP、Notch1、c-MYC和cyclin E表达增加。多种蛋白和micro-RNAs的表达异常可引起FBXW7功能失调。TRIM25直接降解FBXW7α促进肿瘤的发生发展。miR-155-3p、miR-92a、miR-27b、miR-770在体外实验中促进肝癌细胞增殖。此外，FBXW7在原发性肝癌患者组织中显著下调且与较差的临床病理特点(肿瘤体积大，血管侵犯，高病理学分级，高TNM分期)相关。然而，从FBXW7入手的靶向治疗仍是目前的一大难题。作为重要的抑癌蛋白，未来的研究需致力于FBXW7蛋白及其上游分子的靶向治疗，旨在原发性肝癌患者体内恢复抑癌FBXW7蛋白活性。</p><p>然而，该综述仅仅阐述了FBXW7与原发性肝癌发生的部分机制，更多的FBXW7底物蛋白及信号通路仍然未知。此外，FBXW7与原发性肝癌的临床特征虽有联系，但其用于临床诊断的具体价值仍需进一步探索。至于针对FBXW7及其上游分子的治疗，目前也仅仅停留在体外实验的阶段，分子靶向药物的开发还有很长的路要走。显然，我们对于FBXW7的认识还远远不足，这需要更多的研究来揭示FBXW7具体功能，以及其原发性肝癌发生发展中的作用机制，最终为原发性肝癌的靶向治疗开辟新的道路。</p></sec><sec id="s9"><title>文章引用</title><p>谭智勇,李春明,龚建平. FBXW7与原发性肝癌发生的关系Relationship between FBXW7 and the Occurrence of Primary Liver Cancer[J]. 临床医学进展, 2021, 11(03): 1362-1366. https://doi.org/10.12677/ACM.2021.113194</p></sec><sec id="s10"><title>参考文献</title></sec></body><back><ref-list><title>References</title><ref id="hanspub.41330-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">Dang, F., Nie, L. and Wei, W. (2021) Ubiquitin Signaling in Cell Cycle Control and Tumorigenesis. Cell Death and Differentiation, 28, 427-438. &lt;br&gt;https://doi.org/10.1038/s41418-020-00648-0</mixed-citation></ref><ref id="hanspub.41330-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">Lauinger, L. and Kaiser, P. (2021) Sensing and Signaling of Methionine Metabolism. Metabolites, 11, 83. 
&lt;br&gt;https://doi.org/10.3390/metabo11020083</mixed-citation></ref><ref id="hanspub.41330-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">Yumimoto, K. and Nakayama, K.I. (2020) Recent Insight into the Role of FBXW7 as a Tumor Suppressor. Seminars in Cancer Biology, 67, 1-15. &lt;br&gt;https://doi.org/10.1016/j.semcancer.2020.02.017</mixed-citation></ref><ref id="hanspub.41330-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">Huo, W., Qi, F. and Wang, K. (2020) Long Non-Coding RNA FER1L4 Inhibits Prostate Cancer Progression via Sponging miR-92a-3p and Upregulation of FBXW7. Cancer Cell International, 20, Article No. 64.  
&lt;br&gt;https://doi.org/10.1186/s12935-020-1143-0</mixed-citation></ref><ref id="hanspub.41330-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">Yeh, C.H., Bellon, M. and Nicot, C. (2018) FBXW7: A Critical Tumor Suppressor of Human Cancers. Molecular Cancer, 17, Article No. 115. &lt;br&gt;https://doi.org/10.1186/s12943-018-0857-2</mixed-citation></ref><ref id="hanspub.41330-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">Bogdanovic, A., Bulajic, P., Masulovic, D., et al. (2021) Liver Resection versus Transarterial Chemoembolization for Huge Hepatocellular Carcinoma: A Propensity Score Matched Analysis. Scientific Reports, 11, Article No. 4493.  
&lt;br&gt;https://doi.org/10.1038/s41598-021-83868-9</mixed-citation></ref><ref id="hanspub.41330-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">Akinyemiju, T., Abera, S., Ahmed, M., et al. (2017) The Burden of Primary Liver Cancer and Underlying Etiologies from 1990 to 2015 at the Global, Regional, and National Level: Results from the Global Burden of Disease Study 2015. JAMA Oncology, 3, 1683-1691. &lt;br&gt;https://doi.org/10.1001/jamaoncol.2017.3055</mixed-citation></ref><ref id="hanspub.41330-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">Wang, D., Pierce, A., Veo, B., et al. (2021) A Regulatory Loop of FBXW7-MYC-PLK1 Controls Tumorigenesis of MYC-Driven Medulloblastoma. Cancers, 13, 387. &lt;br&gt;https://doi.org/10.3390/cancers13030387</mixed-citation></ref><ref id="hanspub.41330-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">Zhong, L., Zhang, Y., Li, M., et al. (2020) E3 Ligase FBXW7 Restricts M2-Like Tumor-Associated Macrophage Polarization by Targeting c-Myc. Aging, 12, 24394-24423. &lt;br&gt;https://doi.org/10.18632/aging.202293</mixed-citation></ref><ref id="hanspub.41330-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">Hynes-Smith, R.W., Wittorf, K.J. and Buckley, S.M. (2020) Regulation of Normal and Malignant Hematopoiesis by FBOX Ubiquitin E3 Ligases. Trends in Immunology, 41, 1128-1140. &lt;br&gt;https://doi.org/10.1016/j.it.2020.10.003</mixed-citation></ref><ref id="hanspub.41330-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">Li, K., Wang, F., Yang, Z.N., et al. (2020) TRIB3 Promotes MYC-Associated Lymphoma Development through Suppression of UBE3B-Mediated MYC Degradation. Nature Communications, 11, Article No. 6316.  
&lt;br&gt;https://doi.org/10.1038/s41467-020-20107-1</mixed-citation></ref><ref id="hanspub.41330-ref12"><label>12</label><mixed-citation publication-type="other" xlink:type="simple">Zhang, Q., Li, X., Cui, K., et al. (2020) The MAP3K13-TRIM25-FBXW7α Axis Affects c-Myc Protein Stability and Tumor Development. Cell Death and Differentiation, 27, 420-433. &lt;br&gt;https://doi.org/10.1038/s41418-019-0363-0</mixed-citation></ref><ref id="hanspub.41330-ref13"><label>13</label><mixed-citation publication-type="other" xlink:type="simple">Wu, W.J., Shi, J., Hu, G., et al. (2016) Wnt/Β-Catenin Signaling Inhibits FBXW7 Expression by Upregulation of microRNA-770 in Hepatocellular Carcinoma. Tumour Biology, 37, 6045-6051.  
&lt;br&gt;https://doi.org/10.1007/s13277-015-4452-5</mixed-citation></ref><ref id="hanspub.41330-ref14"><label>14</label><mixed-citation publication-type="other" xlink:type="simple">Wang, Y., Liu, Z., Yao, B., et al. (2017) Long Non-Coding RNA CASC2 Suppresses Epithelial-Mesenchymal Transition of Hepatocellular Carcinoma Cells through CASC2/miR-367/FBXW7 Axis. Molecular Cancer, 16, Article No. 123. &lt;br&gt;https://doi.org/10.1186/s12943-017-0702-z</mixed-citation></ref><ref id="hanspub.41330-ref15"><label>15</label><mixed-citation publication-type="other" xlink:type="simple">Tang, B., Lei, B., Qi, G., et al. (2016) MicroRNA-155-3p Promotes Hepatocellular Carcinoma Formation by Suppressing FBXW7 Expression. Journal of Experimental &amp; Clinical Cancer Research, 35, Article No. 93.  
&lt;br&gt;https://doi.org/10.1186/s13046-016-0371-6</mixed-citation></ref><ref id="hanspub.41330-ref16"><label>16</label><mixed-citation publication-type="other" xlink:type="simple">Tang, X., Yang, W., Shu, Z., et al. (2019) MicroRNA-223 Promotes Hepatocellular Carcinoma Cell Resistance to Sorafenib by Targeting FBW7. Oncology Reports, 41, 1231-1237. &lt;br&gt;https://doi.org/10.3892/or.2018.6908</mixed-citation></ref><ref id="hanspub.41330-ref17"><label>17</label><mixed-citation publication-type="other" xlink:type="simple">Deng, P. and Wu, Y. (2019) Knockdown of miR-106a Suppresses Migration and Invasion and Enhances Radiosensitivity of Hepatocellular Carcinoma Cells by Upregulating FBXW7. International Journal of Clinical and Experimental Pathology, 12, 1184-1193.</mixed-citation></ref><ref id="hanspub.41330-ref18"><label>18</label><mixed-citation publication-type="other" xlink:type="simple">Zhu, Z.Z., Bao, L.L., Zhao, K., et al. (2019) Copy Number Aberrations of Multiple Genes Identified as Prognostic Markers for Extrahepatic Metastasis-Free Survival of Patients with Hepatocellular Carcinoma. Current Medical Science, 39, 759-765. &lt;br&gt;https://doi.org/10.1007/s11596-019-2103-6</mixed-citation></ref><ref id="hanspub.41330-ref19"><label>19</label><mixed-citation publication-type="other" xlink:type="simple">Tu, K., Yang, W., Li, C., et al. (2014) FBXW7 Is an Independent Prognostic Marker and Induces Apoptosis and Growth Arrest by Regulating Yap Abundance in Hepatocellular Carcinoma. Molecular Cancer, 13, Article No. 110.  
&lt;br&gt;https://doi.org/10.1186/1476-4598-13-110</mixed-citation></ref><ref id="hanspub.41330-ref20"><label>20</label><mixed-citation publication-type="other" xlink:type="simple">Wang, X., Zhang, J., Zhou, L., et al. (2015) FBXW7 Regulates Hepatocellular Carcinoma Migration and Invasion via Notch1 Signaling Pathway. International Journal of Oncology, 47, 231-243. &lt;br&gt;https://doi.org/10.3892/ijo.2015.2981</mixed-citation></ref><ref id="hanspub.41330-ref21"><label>21</label><mixed-citation publication-type="other" xlink:type="simple">Tu, K., Zheng, X., Zan, X., et al. (2012) Evaluation of FBXW7 Expression and Its Correlation with the Expression of c-Myc, Cyclin E and p53 in Human Hepatocellular Carcinoma. Hepatology Research, 42, 904-910.  
&lt;br&gt;https://doi.org/10.1111/j.1872-034X.2012.01005.x</mixed-citation></ref></ref-list></back></article>